Alkermes plc has been upgraded from Hold to Buy due to its robust revenue growth driven by the acquisition of Avadel and the launch of Lumryz, which are expected to propel over 20% revenue growth by 2026. The company projects adjusted EBITDA between $370–410 million despite a GAAP net loss. Strong Phase 2 data for Alixorexton in narcolepsy and idiopathic hypersomnia, along with advances in its orexin pipeline, support significant long-term revenue potential. Management changes and steady growth in core products further strengthen Alkermes' strategic position in sleep and central nervous system disorders, indicating a positive outlook.
Oracle reported a strong quarter, surpassing revenue and earnings per share expectations driven by accelerating cloud infrastructure growth and strong AI demand. Despite a 770 basis point year-over-year gross margin decline and negative free cash flo...
On the 25th anniversary of 9/11, billionaire John Catsimatidis warned that countries like Russia, North Korea, China, and Iran are actively trying to undermine President Donald Trump ahead of the November election. He expressed disappointment with Ca...
Lakeland Industries remains a Buy, but the price target was lowered from $18.00 to $14.50 due to revised margin expectations and increased litigation risk from new PFAS multidistrict lawsuits. While gross margin improved to 37%, only half of that is ...
Western Digital, a leading hard disk drive (HDD) provider, reported a 44% year-over-year revenue increase in Q4 driven by strong demand from cloud and AI workloads. Cloud customers made up 89% of revenue, with shipments growing 22% in exabytes. Gross...
VinFast and GSM have announced new senior leadership appointments to support their global expansion. Pham Nhat Quan Anh becomes CEO of VinFast Global and Chairman and CEO of VinFast Vietnam, succeeding Pham Nhat Vuong. Nguyen Quoc Tuan is named Chair...
